AR075058A1 - ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES AND MANUFACTURING PROCESS - Google Patents

ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES AND MANUFACTURING PROCESS

Info

Publication number
AR075058A1
AR075058A1 ARP100100462A ARP100100462A AR075058A1 AR 075058 A1 AR075058 A1 AR 075058A1 AR P100100462 A ARP100100462 A AR P100100462A AR P100100462 A ARP100100462 A AR P100100462A AR 075058 A1 AR075058 A1 AR 075058A1
Authority
AR
Argentina
Prior art keywords
phenylephrine
loratadine
film
layer
pharmaceutical composition
Prior art date
Application number
ARP100100462A
Other languages
English (en)
Inventor
Salgado Lopez Raul Garcia
Aguilar Juan Aurelio Senosiain
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2009001925A priority Critical patent/MX2009001925A/es
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of AR075058A1 publication Critical patent/AR075058A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Abstract

Reivindicacion 1: Una cápsula de liberacion prolongada que contiene de 2.5 mg hasta 20.0 mg de loratadina y de 10.0 mg hasta 180 mg de fenilefrina, o sus sales farmacéuticamente aceptables, caracterizada porque comprende microesferas con la siguiente configuracion: a) un nucleo inerte recubierto con una primera película o capa formada por el 30 - 70 % de la dosis de fenilefrina y al menos un polímero adhesivo; b) una segunda película o capa formada por al menos un polímero retardante; y c) una tercera película o capa formada por e]. 30 - 70% de la dosis de fenilefrina, loratadina y al menos un polímero adhesivo; en donde fenilefrina presenta liberacion modificada y loratadina presenta liberacion inmediata. Reivindicacion 4: El uso de la cápsula de liberacion prolongada de la reivindicacion 1 para la preparacion de un medicamento indicado en el tratamiento de rinitis alérgica, congestion nasal y prurito oculo nasal.Claim 1: An extended-release capsule containing 2.5 mg to 20.0 mg of loratadine and 10.0 mg to 180 mg of phenylephrine, or its pharmaceutically acceptable salts, characterized in that it comprises microspheres with the following configuration: a) an inert nucleus coated with a first film or layer formed by 30-70% of the dose of phenylephrine and at least one adhesive polymer; b) a second film or layer formed by at least one retarding polymer; and c) a third film or layer formed by e]. 30-70% of the dose of phenylephrine, loratadine and at least one adhesive polymer; where phenylephrine has modified release and loratadine has immediate release. Claim 4: The use of the extended-release capsule of claim 1 for the preparation of a medicament indicated in the treatment of allergic rhinitis, nasal congestion and nasal eye pruritus.
ARP100100462A 2009-02-20 2010-02-17 ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES AND MANUFACTURING PROCESS AR075058A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2009001925A MX2009001925A (es) 2009-02-20 2009-02-20 ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES.

Publications (1)

Publication Number Publication Date
AR075058A1 true AR075058A1 (es) 2011-03-09

Family

ID=42633450

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100462A AR075058A1 (es) 2009-02-20 2010-02-17 ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES AND MANUFACTURING PROCESS

Country Status (9)

Country Link
US (1) US20120064155A1 (es)
AR (1) AR075058A1 (es)
CO (1) CO6410284A2 (es)
CR (1) CR20110436A (es)
DO (1) DOP2011000267A (es)
HN (1) HN2011002258A (es)
MX (1) MX2009001925A (es)
PE (1) PE20120173A1 (es)
WO (1) WO2010094996A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795571B2 (en) 2014-09-19 2017-10-24 The Procter & Gamble Company Pulsed release phenylephrine dosage forms
MX2017001192A (es) * 2017-01-26 2018-07-25 Laboratorios Liomont S A De C V PHARMACEUTICAL COMPOSITION OF LORATADINE, PHENYLEFRINE, PARACETAMOL AND AMANTADINE FOR ORAL ADMINISTRATION, FOR THE TREATMENT OF ALOPATHY RELATED TO A COMMON COLD.
US10278930B2 (en) 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255968B (it) * 1992-11-27 1995-11-17 Composizioni farmaceutiche contenenti acido ursodesossicolico
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
SG172664A1 (en) * 2006-06-01 2011-07-28 Schering Plough Healthcare Phenylephrine pharmaceutical formulations and compositions for colonic absorption
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
WO2007143156A1 (en) * 2006-06-01 2007-12-13 Schering Corporation Phenylphrine pulsed release formulations and pharmaceutical compositions

Also Published As

Publication number Publication date
WO2010094996A1 (es) 2010-08-26
US20120064155A1 (en) 2012-03-15
MX2009001925A (es) 2010-08-20
HN2011002258A (es) 2014-06-16
CR20110436A (es) 2011-10-24
PE20120173A1 (es) 2012-03-24
DOP2011000267A (es) 2011-12-31
CO6410284A2 (es) 2012-03-30

Similar Documents

Publication Publication Date Title
AR079145A1 (es) PROBABILISTIC SIMULATION OF THE PROPAGATION OF UNDERGROUND FRACTURES
BR112012007501B1 (pt) cooling device and radiator for hybrid vehicle
AR070418A1 (es) Metodo y aparato para determinar la dilatacion de un material mediante un dispositivo sensor de error de foco
BR112012015977B1 (pt) COMPONENT OF AN IONIC POLYMER, COMPOSITION OF PROLONGED DRUG RELEASE MICROPARTICLE, AND, METHOD FOR PREPARING THE PROLONGED DRUG RELEASE COMPOSITION
AR076858A1 (es) Procedimiento de control de inmersion y equipo para un cable de registro sismico estacionario
BR112012010436A2 (pt) streamer cable, seismic spreading, and method for manufacturing a streamer cable
DOP2011000267A (es) Composicion farmaceutica oral para uso en enfermedades respiratorias
AR078101A1 (es) Metodos para diagnosticar la diabetes y determinar la eficacia de tratamientos
AR080667A1 (es) Un nutriente para plantas que se obtienen de la cascara del arroz y un proceso de preparacion del mismo
AR078292A1 (es) Unidad portatil para transvasar combustible
AR070368A2 (es) Procedimiento para la preparacion de una composicion de vacuna que comprende un inmunoestimulante un antigeno y una sal metalica y uso de dicha composicion para preparar un medicamento.composicion de vacuna
AR076638A1 (es) COMPOSITION OF BIODEGRADABLE AND ANTI-LONG ECOLOGICAL LUBRICANT FLUID FOR HYDRAULIC SYSTEMS
BR112012011323A2 (pt) method and system for detecting hand presence in a minimally invasive surgical system
AR072597A4 (es) Dispositivo manual para quitar elementos extranos de la arena
AR070462A1 (es) Metodo y composicion para tratar una afeccion diabetica. proceso para preparar dicha composicion. uso.
AR070445A4 (es) Elemento laminar para el colgado de articulos personales
AR070435A1 (es) DISPOSITIVO GENERADOR DE ENERGíA A PARTIR DE CORRIENTES DE AGUA
AR070426A4 (es) Separador de bultos paralelepipedicos adyacentes palletizados
AR070425A4 (es) Dispositivo de acople para envases plasticos
AR070396A1 (es) Lampara para semaforo
AR070399A2 (es) Anticuerpos anti- erbb2 humanizados y tratamiento con anticuerpos anti-erb2. articulo de fabricacion. composicion. inmunoconjugado. acido nucleico. vector. celula huesped. proceso para preparar anticuerpo humanizado.
AR070373A1 (es) Generador eolico asincronico
AR070369A2 (es) Equipo (kit) que comprende un inmunoestimulante y un antigeno
AR070417A1 (es) Horno de seguridad desmontable
AR070419A1 (es) Procedimiento para el monitoreo y centrado de uno o mas haces de particulas energeticas

Legal Events

Date Code Title Description
FC Refusal